VEGFA and hepatocellular carcinoma: ICIs have become a key treatment option for HCC, with the combination of the anti‐PD‐L1 antibody atezolizumab and the anti‐vascular endothelial growth factor antibody bevacizumab now being the preferred first‐line therapy for advanced HCC [84].